By VETTAPHARMA reporter: Modella AI, a biomedical artificial intelligence company focused on life sciences, has announced it has been acquired by AstraZeneca, expanding the firms’ existing collaboration to advance the use of multi-modal AI foundation models and AI agents across the global oncology portfolio. The acquisition marks a strategic milestone for both companies, embedding Modella AI’s generative and agentic AI platform into AstraZeneca’s oncology research and development organization.
The acquisition builds on a multi-year agreement first announced in July 2025 and integrates Modella AI’s technology into AstraZeneca’s clinical development and biomarker discovery efforts. AstraZeneca plans to use the AI platform to support data-driven decision-making and generate biological and clinical insights more efficiently across data-intensive workflows in oncology.
Gabi Raia, Chief Commercial Officer of Modella AI, highlighted the growing complexity and data demands of oncology drug development and emphasized the need for AI solutions that can operate effectively in global clinical settings. Jill Stefanelli, PhD, co-founder and CEO of Modella AI, noted that joining AstraZeneca will allow the company’s AI models to accelerate development and help improve outcomes for patients with cancer.
Modella AI was founded at the intersection of pathology, clinical data, and advanced generative AI to tackle challenges in oncology. Its multi-modal foundation models and AI agents are designed to empower clinicians, improve patient outcomes, and transform medical research workflows.
Jorge Reis-Filho, Chief of AI for Science Innovation at AstraZeneca, described the acquisition as a step toward integrating state-of-the-art AI technology to enable the development of targeted therapeutics and diagnostics across the oncology portfolio. Financial terms of the transaction were not disclosed.
Source Credit:
Modella AI. (2026, January 13). Modella AI announces acquisition by AstraZeneca to advance AI-driven oncology R&D at global scale. Click here
Disclaimer:
The contents published on this platform are intended solely for informational and educational purposes. Reports, summaries, and discussions related to clinical trials are based on publicly available data, press releases, scientific publications, and regulatory disclosures available at the time of reporting. The information provided does not constitute medical advice, diagnosis, treatment recommendations, or endorsement of any drug, therapy, or clinical outcome. Clinical trial data are subject to change as studies progress, and results discussed may be preliminary, incomplete, or not yet peer-reviewed. Readers are strongly encouraged to refer to the original clinical trial records, regulatory filings, peer-reviewed articles or related sources for complete, accurate, and up-to-date information. Healthcare professionals and patients should consult qualified medical professionals and relevant regulatory authorities before making any healthcare or treatment decisions. Images used on this platform are illustrative in nature and are intended for conceptual and representational purposes only. They may not depict actual products, facilities, individuals, or events. The platform and its contributors disclaim any liability for actions taken based on the information presented.
